Julie Côté, MD, on Multiple Myeloma: Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients
2022 ASH Annual Meeting and Exposition
Julie Côté, MD, of CHU de Québec–Université Laval, discusses findings from the Canadian Myeloma Research Group database, which showed that integrating bortezomib and lenalidomide into the autologous stem cell transplant (ASCT) sequence produces a median overall survival rate ≥ 10 years in most patients with newly diagnosed multiple myeloma. These observations highlight the contribution of post-ASCT maintenance, particularly lenalidomide given until disease progression, when used in multiple patient groups including those with and without high risk, as well as those requiring a second induction regimen (Abstract 117).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The standard of care for multiple myeloma patients with a new diagnosis and for patients that are transplant eligible in Canada, is to first to start with a bortezomib-based induction and then go with a high dose melphalan, an autologous stem cell transplant, followed by lenalidomide maintenance until progression.
So, the aim of our study was really to look at the outcomes in details of this patient population in Canada, in the real world setting. So, using our national myeloma database from the C M R G, known as the Canadian Myeloma Research Group, all the patients who received an autologous stem cell transplant for multiple myeloma in the first line setting, from January 2007 to December 2021, were included. So, this gives us 3,800 patients approximately, and most of them received a bortezomib-based induction, mostly being CYBORD, in 72%. We had mostly single-transplant patients. Only 8% received tandem transplant, and it was mostly in high risk patients.
18% of the population were high risk. And what's interesting to see is that, overall with one single transplant, median PFS was around 35 months, and median overall survival was around 10 years. And median overall survival was around 10 years for approximately all subgroup patients, except in high-risk patients; so high-risk patients had inferior outcomes. For consolidation therapy, it's not root routinely available in Canada, so only a few patients received that kind of therapy, about 5%. It was mostly a regimen combining a ubiquitin and a proteasome inhibitor. Globally, consolidation leads to a better PFS, but with no significant gain on OS.
For maintenance therapy, about half of our court received maintenance therapy, and it was mostly lenalidomide-based regimen. Maintenance therapy was leading to a significant benefit on PFS and OS, in all risk subgroups, although it does not completely abrogate the negative impact of high risk cytogenetics in the high risk patients.
Globally, with the lenalidomide-based maintenance regimen, the PFS was around 4.5 years, and the overall survival around 13 years. As you can see, this real world data covers about 15 years in our court of timeline. And it really shows that the integration of bortezomib and lenalidomide in the transplant sequence, leads to an overall survival of about 10 years in most autologous stem cell transplant patient. It also highlights the beneficial contribution of lenalidomide mainstream therapy in patients without and with high risks, and also in patients receiving a second course of induction. Indeed, these patients had significantly inferior outcomes compared to those receiving only one induction regimen, but with maintenance therapy, outcomes would were comparable even though you received one or two induction regimen. So, this really highlights the importance of maintenance therapy in these subgroups.
Right now, further analysis are ongoing, to look at relationship between treatment outcomes, patients characteristics, and these results will really serve as Canadian benchmarks to compare with newer approaches that are eventually coming.
Related Videos
The ASCO Post Staff
Tycel J. Phillips, MD, of the City of Hope National Medical Center, discusses data that showed fixed-duration glofitamab monotherapy induced high and durable complete response rates in patients with mantle cell lymphoma (MCL) who received obinutuzumab pretreatment. This is one of the largest data sets and longest follow-ups reported with a CD20/CD3 bispecific monoclonal antibody for patients with relapsed or refractory MCL (Abstract 74).
The ASCO Post Staff
Kathryn R. Tringale, MD, of Memorial Sloan Kettering Cancer Center, discusses an assessment of 559 patients with primary central nervous system (CNS) lymphoma and the factors associated with consolidation therapy selection, outcomes after consolidation therapy accounting for patient factors, and patterns of disease failure. The initial treatment response was prognostic and predictive of relapse patterns (Abstract 557).
The ASCO Post Staff
Smita Bhatia, MD, MPH, of the Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, discusses study findings that showed key somatic mutations in the peripheral blood stem cell product increases the risk of developing therapy-related myeloid neoplasms (Abstract 119).
The ASCO Post Staff
Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discusses preliminary results from the dose-expansion phase of the CC-92480-MM-001 Trial, which showed promising efficacy in patients with relapsed and refractory multiple myeloma, including those with prior BCMA-targeted therapies. Patients in these two groups had an overall response rate of 40% and 50%, respectively. The results support the development of mezigdomide, currently being evaluated in combination with standard therapies in multiple myeloma as part of a large, ongoing phase I/II trial (NCT03989414) and planned phase III studies (Abstract 568).
The ASCO Post Staff
Tomohiro Aoki, MD, PhD, of the University of British Columbia and the Centre for Lymphoid Cancer at BC Cancer, discusses a novel prognostic model applicable to patients with relapsed or refractory classical Hodgkin lymphoma who were treated with autologous stem cell transplantation. The model has shown the interaction between the biomarker CXCR5 on HRS cells (Hodgkin and Reed/Sternberg cells, hallmarks of Hodgkin lymphoma) with specific follicular T helper cells and macrophages, a prominent crosstalk axis in relapsed disease. This insight opens new avenues to developing predictive biomarkers (Abstract 71).
